@FierceBiotech: Biogen Idec preps for a big leap into the anti-TNF blockbuster biosimilars market. More | Follow @FierceBiotech
@JohnCFierce: "Amy Schulman and Pfizer have agreed to separate." What, no retirement? More | Follow @JohnCFierce
@DamianFierce: Amgen keeps with the PCSK9 pack in its first Phase III results for evolocumab. News | Follow @DamianFierce
@EmilyMFierce: Researchers find a possible drug target for undruggable melanoma. Story | Follow @EmilyMFierce
> Boehringer Ingelheim's Pradaxa proved just as effective as warfarin in preventing blood clots, giving the company hope of winning a broader indication for the drug. News
> Pfizer's ($PFE) Amy Schulman is no longer with the company, a surprise departure revealed just weeks before she was meant to take the helm of the company's vaccines, oncology and consumer healthcare business. Article
> Researchers at Vanderbilt University have discovered some promising drug targets for hard-to-treat melanomas previously considered undruggable. More
@FierceMedDev: TruTouch Technologies (biometric alcohol sensor) names Marathon's Bruce Berger CEO. Release | Follow @FierceMedDev
@MarkHFierce: In an interesting twist, ViewRay's new $30M round includes an investment from a Chinese distributor. Story | Follow @MarkHFierce
@MichaelGFierce: Alnylam begins PhII trial for amyloidosis RNAi treatment. Item from FierceDrugDelivery | Follow @MichaelGFierce
@GalenMoore: Boston Scientific recruits a veteran Silicon Valley investor amid its M&A push. More | Follow @GalenMoore
> Belgium's Cardio3 Biosciences gets $5.5M to advance heart catheter, stem cell treatment. Item
> SynCardia's $14M infusion will fuel formal testing of a smaller-sized heart implant. Story
Pharma News
@FiercePharma: Whoa: Amy Schulman is out, rather abruptly, at Pfizer. She was one of the three division chiefs chosen by CEO Ian Read earlier this year. | Follow @FiercePharma
@EricPFierce: Teva renegs on plans to build a new API plant in India. Story from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: Pfizer names Albert Bourla Group President; Vaccines, Oncology and Consumer Healthcare Business. Release | Follow @CarlyHFierce
> Almirall eyes growth in U.S., dermatology with $400M Aqua Pharma buyout. Story
> Traders bet Novartis CEO will bail out of its $14B Roche stake. More
> Amy Schulman, tapped to lead a new Pfizer division, makes an abrupt exit. News
> GlaxoSmithKline scraps doc payments, sales-rep quotas in global marketing revamp. Article
> Supreme Court won't take up ex-InterMune CEO's free-speech defense. Report
> Chinese whistleblower tags Shanghai Pharma with bribery allegations. Item
Pharma Manufacturing News
> China rounds up hundreds in crackdown against drug counterfeiters. More
> Novartis' OTC recall is tied to a contractor this time. Story
> Novartis to shed Alcon plant, 300 jobs next year. News
> What's a makeover cost these days? For AstraZeneca's distribution hub, $100M. Article
> Teva reneges on its proposal to build a $141M API plant in India. Report
> Wales fines companies £120,000 for worker accidents. Item
Biotech Research News
> Congressional budget deal would ease NIH sequester cuts. Story
> Report: Life science research needs standards to curb irreproducible studies. More
> CIRM awards $61M for cancer research. Item
> Researchers find possible drug targets for undruggable melanomas. News
> Blood vessel breakdown in the brain may be linked to Alzheimer's. Report
> Glaxo compound slows Lou Gehrig's disease in animal models. Article